PD-1T TILs as precision biomarker in NSCLC 77 2 Table S6. The relationship between PD-1T and clinicopathological variables as continuous variable. PD-1T TILs per mm2 (quantiles) 0% 25% 50% 75% 100% Sex P=0.67 Male (n=62) 0 25 67 201 1875 Female (n=58) 1 26 69 199 868 Smoking P=0.86 Ex (n=93) 0 24 66 194 1875 Current (n=16) 7 40 82 207 457 PS P=0.19 0 (n=36) 2 25 85 238 868 1 (n=65) 0 27 80 181 1875 ≥2 (n=19) 0 26 66 118 457 Pathology P= 0.60 Adeno (n=76) 0 25 63 184 1875 Squamous (n=21) 2 31 139 213 595 LCNEC, NSCLC-type (n=3) 0 21 82 264 552 NSCLC, NOS (n=20) 7 37 67 97 126 Mutations P= 0.42 KRAS positive (n=51) 0 30 80 200 1875 KRAS negative (n=43) 2 20 66 212 595 KRAS unknown (n=26) 0 26 101 185 298 Brain metastases P=0.38 Yes (n=21) 0 29 60 152 828 No (n=99) 0 25 80 207 1875 Treatment P=0.81 Nivolumab (n=94) 0 25 68 206 1875 Pembrolizumab (n=26) 0 26 75 185 868 Line of treatment P= 0.13 1 (n=1) 2 (n=87) 0 25 66 187 868 >2 (n=32) 0 26 104 258 1875
RkJQdWJsaXNoZXIy MTk4NDMw